Kolexia
Freyer Gilles Oncologie médicale
Freyer Gilles
Oncologie médicale
Hôpital Lyon Sud
Pierre-Bénite, France
336 Activités
6 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du sein Carcinome épithélial de l'ovaire Carcinomes Métastase tumorale Neutropénie Récidive tumorale locale Tumeurs de la prostate Maladie trophoblastique gestationnelle

Collaborateurs

Voir plus
You Benoit
You Benoit
Hôpital Lyon Sud, Pierre-Bénite, France
Tod Michel
Tod Michel
Hôpital La Croix-Rousse, Lyon, France
Leger Falandry Claire
Leger Falandry Claire
Hôpital Lyon Sud, Pierre-Bénite, France
Peron Julien
Peron Julien
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Lilly
47 collaboration(s)
Dernière en 2023
Novartis
39 collaboration(s)
Dernière en 2023
GSK
32 collaboration(s)
Dernière en 2023
MSD
21 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
JCO clinical cancer informatics   19 février 2024
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Breast (Edinburgh, Scotland)   09 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.
Geburtshilfe und Frauenheilkunde   08 février 2024
NIRVANA-1: Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery
Essai Clinique (ARCAGY/ GINECO GROUP)   29 janvier 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   19 janvier 2024
AMBRE: Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease
Essai Clinique (Unicancer)   19 janvier 2024
Cancers gynécologiques, "le" cancer n'est pas une seule maladie
Youtube @ Pourquoi Docteur   12 janvier 2024